On Monday, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) entered into an exclusive license agreement with Biosion Inc for ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Fintel reports that on November 18, 2024, Piper Sandler upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

Jefferies analyst Roger Song upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of $7.00. Don't Miss our Black Friday Offers: Roger Song’s ...

Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120% ...

Shares of Aclaris Therapeutics (NASDAQ:ACRS) rallied 53% Monday after the company announced it had exclusively licensed two ...

Aclaris Therapeutics (ACRS) shares surge 13% after exclusive global license deal for potential best-in-class biologics assets to bolster its pipeline.

Aclaris Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.72. The stock has a market capitalization of ...